Skip to main content

Table 1 Experimental groups and immunization protocol

From: Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine

Group no

Antigen/Adjuvant(s)

Ag (μg/mouse)

Adjuvants (μg/mouse)

Prime*

Boost1**

Boost 2***

CpG

MPL

QS-21

1 (n = 9)

cd-HAP/−

10

5

5

–

–

–

2 (n = 9)

cd-HAP/CpG

10

5

5

10

–

–

3 (n = 9)

cd-HAP/MPL

10

5

5

–

10

–

4 (n = 9)

cd-HAP/QS-21

10

5

5

–

–

10

5 (n = 9)

cd-HAP/CpG + MPL + QS-21

10

5

5

5

5

5

6 (n = 9)

−/1 × PBS

–

–

–

   

7 (n = 9)

−/CpG

–

–

–

10

–

–

8 (n = 9)

−/MPL

–

–

–

–

10

–

9 (n = 9)

−/QS-21

–

–

–

–

–

10

10 (n = 9)

−/CpG + MPL + QS-21

–

–

–

5

5

5

  1. Female BALB/c mice (n = 90) were distributed into 10 groups and immunized subcutaneously with the antigen alone or in combination with different adjuvants. The control groups received 1 × PBS alone or with each adjuvant. Sera samples were collected from the tail vein on days 10, 24, 38, and 180 after the first immunization for further analysis
  2. *Day 0
  3. **Day 14
  4. ***Day 28